Express options and Interac e-Transfer are available at checkout
Understanding their current regulatory positions provides insight into their availability, pricing, and potential timeline for expanded clinical use
Por ejemplo, semaglutida es un agonista simple, que solo activa el receptor GLP-1
Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks
Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) demonstrated significant reductions in major adverse cardiovascular events, while others showed cardiovascular safety without superiority
It should include: Clinical screening for contraindications, interacting medicines, and relevant medical history
